Journal: Vaccine

Article Title: Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2

doi: 10.1016/j.vaccine.2022.07.023

Figure Lengend Snippet: Fc-mediated functions and RBD-ACE2 binding inhibition of specific serum anti-RBD immunoglobulins . Figure shows ADCC (A) and ADCP (B) Fc-mediated functions of serum anti-RBD immunoglobulin in 20 individuals early after two doses of Coronavac (t 1 ) and after heterologous booster with BNT162b2 (t 3 ). Endpoint titers were calculated by interpolating the reciprocal of serum dilutions to baseline, whose values were determined for each plate as the mean signal in absence of serum plus three standard deviations. Inhibition of RBD-ACE2 binding (C) and serum anti-RBD IgG levels (D) were measured in the same samples, showing a similar behavior over time. Comparison of the RBD-ACE2 binding inhibition activity against SARS-CoV-2 Wuhan and Omicron variants were carried out by sVNT in these 20 samples (E). Numbers represents median values and the interquartile range (in parentheses). Comparisons between groups were carried out using Wilcoxon test. *p < 0.05, ** p = 0.01–0.001, *** p < 0.001. BAU, binding antibody units; AU, arbitrary units.

Article Snippet: The blockade of RBD-ACE2 interaction by specific anti-SARS-CoV-2 antibodies was analyzed by using an in vitro surrogate virus neutralization test (sVNT; cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit, GenScript®) in serum from individuals who received heterologous vaccination at t 1 and t 2 (post-2D with CoronaVac) and at t 3 and t 4 (post-3D with BNT162b2), according to manufacturer’s instructions.

Techniques: Binding Assay, Inhibition, Comparison, Activity Assay

Journal: Chemical Science

Article Title: Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives

doi: 10.1039/d2sc06665c

Figure Lengend Snippet: Illustration of the LF-sVNT protocol and example sensorgrams. (A) First cycle measuring the binding ability of RBD to ACE2 after neutralization. (B) Second cycle measuring the full binding ability of RBD without neutralization. Reproduced with permission from J. Clin. Microbiol. , 2021, 59 , e0019321, 10.1128/JCM.00193-21.

Article Snippet: Michiels et al. compared the sVNT commercial kit (GenScript cPassTM) with a live virus neutralization assay and Luminex multiplex immunoassay (MIA), and studied two different cohorts using these three methods.

Techniques: Binding Assay, Neutralization